Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

13 sept. 2017 17h27 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer

Company Release no. 19/2017 To: NASDAQ Copenhagen A/S ...
12 sept. 2017 00h00 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Increases Share Capital in Connection with Exercise of Warrants

Company Announcement no. 18/2017 To: NASDAQ Copenhagen...
16 août 2017 11h13 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017

Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017 Highlights Revenue reached tUSD 16,168 in the first half of 2017 representing an...
03 juil. 2017 14h00 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 June 2017

Company Release no. 16/2017 To: NASDAQ Copenhagen A/S ...
21 juin 2017 17h00 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program

Company Release no. 15/2017 To: NASDAQ Copenhagen A/S ...
14 juin 2017 23h00 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Increases Share Capital in Connection with Exercise of Warrants

Company Release no. 14/2017 To: NASDAQ Copenhagen...
05 juin 2017 20h38 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S Announces Agreement with Chiesi Farmaceutici S.p.A. to Commercialize Envarsus XR in China

Company Release no. 13/2017 To: NASDAQ Copenhagen A/S ...
05 juin 2017 02h55 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S and Endo Ventures Limited Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Envarsus XR® in Canada

Investor News no. 04/2017 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 05 June...
16 mai 2017 11h21 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2017

Highlights It is now estimated that over 6,000 patients in the US and Europe are being treated with Envarsus XR. In the US, prescription growth of Envarsus in the first quarter...
29 avr. 2017 18h00 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 30 April 2017

Company Release no. 11/2017 To: NASDAQ Copenhagen...

Page précédente